Effects of switching to rituximab from ongoing first-line injectable therapies in patients with relapsing-remitting multiple sclerosis

Trial Profile

Effects of switching to rituximab from ongoing first-line injectable therapies in patients with relapsing-remitting multiple sclerosis

Completed
Phase of Trial: Phase II

Latest Information Update: 22 Jun 2016

At a glance

  • Drugs Rituximab (Primary)
  • Indications Multiple sclerosis
  • Focus Therapeutic Use
  • Most Recent Events

    • 22 Jun 2016 New trial record
    • 17 Jun 2016 Primary endpoint of change in mean CSF levels of NFL before and 1 year after rituximab treatment has been met, according to results published in the Neurology.
    • 17 Jun 2016 Primary endpoint of difference in mean number of Gd+ MRI lesions per patient calculated on the run-in examinations at month -3 and 0 compared with the examinations performed at months 3 and 6 has been met, according to results published in the Neurology.
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top